History and Current status of antibacterial drug development－Fighting drug-resistant bacteria－
| Autor: | Saeki, Kozo |
|---|---|
| Jazyk: | japonština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | 森ノ宮医療大学紀要. 16:1-8 |
| Popis: | 抗菌薬の登場により感染症治療は大きく進歩し，これまでに多様な抗菌薬が開発されてきたが同時に薬剤耐性菌の発生という問題も生じた。薬剤耐性菌は多剤耐性菌も含めて世界中で蔓延し最後の砦であるコリスチンへの耐性化も危惧される一方で，抗菌薬開発の採算性の低さや創薬ターゲットの枯渇から抗菌薬の承認数は1980年代をピークに2010年まで顕著に低下している。しかし抗菌薬開発を促進するプログラムや法律が施行され近年では抗菌薬開発は持ち直しつつあり，創薬ターゲットについても，深海放線菌からメシチリン耐性黄色ブドウ球菌に抗菌活性を示す新たな物質が見出されるなど，未知の環境の微生物が期待されている。 With the advent of antibacterial drugs, the treatment of infectious diseases has made great progress, and various antibacterial drugs have been developed so far, but the problem of drug-resistant bacteria has arisen. Drug-resistant bacteria, including multidrug-resistant bacteria, are widespread all over the world and there is concern that they will become resistant to colistin, which is the last fort antibacterial drug. Antibacterial drug development is not profitable and drug discovery targets are depleted. The number of approvals peaked in the 1980s and has declined significantly until 2010. However, antibacterial drug development has been picking up in recent years due to the enforcement of programs and laws that promote antibacterial drug development, and new substances showing antibacterial activity from deep-sea actinomycetes to methicillin-resistant Staphylococcus aureus have been found. Microorganisms in an unknown environment are expected as new drug discovery targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|